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Abstract
Metallocarboxypeptidase D (CPD) is a membrane-bound component of the trans-Golgi net-
work that cycles to the cell surface through exocytic and endocytic pathways. Unlike other
members of the metallocarboxypeptidase family, CPD is a multicatalytic enzyme with three
carboxypeptidase-like domains, although only the first two domains are predicted to be
enzymatically active. To investigate the enzymatic properties of each domain in human
CPD, a critical active site Glu in domain I and/or II was mutated to Gln and the protein
expressed, purified, and assayed with a wide variety of peptide substrates. CPD with all
three domains intact displays >50% activity from pH 5.0 to 7.5 with a maximum at pH 6.5, as
does CPD with mutation of domain I. In contrast, the domain II mutant displayed >50% activ-
ity from pH 6.5–7.5. CPD with mutations in both domains I and II was completely inactive
towards all substrates and at all pH values. A quantitative peptidomics approach was used
to compare the activities of CPD domains I and II towards a large number of peptides. CPD
cleaved C-terminal Lys or Arg from a subset of the peptides. Most of the identified sub-
strates of domain I contained C-terminal Arg, whereas comparable numbers of Lys- and
Arg-containing peptides were substrates of domain II. We also report that some peptides
with C-terminal basic residues were not cleaved by either domain I or II, showing the impor-
tance of the P1 position for CPD activity. Finally, the preference of domain I for C-terminal
Arg was validated through molecular docking experiments. Together with the differences in
pH optima, the different substrate specificities of CPD domains I and II allow the enzyme to
perform distinct functions in the various locations within the cell.
Introduction
Metallocarboxypeptidases (MCPs) are zinc-dependent enzymes that cleave single amino
acids from the C termini of peptides and proteins [1,2]. The first MCP to be identified was
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carboxypeptidase A1 (CPA1), a pancreatic enzyme that removes C-terminal hydrophobic resi-
dues. In the ensuing decades since the discovery of CPA1, dozens of additional MCPs have
been identified based on sequence and/or structural similarity; these are classified as M14 fam-
ily enzymes by MEROPS [3]. All mammalian MCPs show marked preference for the residue
in the P1’ site, and are selective for either hydrophobic residues, basic residues, or acidic resi-
dues [1,4]. Several M14 gene family members are not active towards conventional carboxypep-
tidase substrates, although it remains possible that they hydrolyze atypical substrates [5–7].
Most of the MCPs show differential patterns of expression. The combination of substrate spec-
ificity and distribution are responsible for the diverse functions of these proteins which ranges
from digestion of food (for carboxypeptidases A1, A2, and B1) to the production of neuropep-
tides and peptide hormones (carboxypeptidase E) and the selective processing of tubulin (cyto-
solic carboxypeptidases) [1,8].
Carboxypeptidase D (CPD) belongs to the M14B subfamily of MCPs and was originally dis-
covered in duck hepatocytes as a 180-kDa membrane-bound glycoprotein (named gp180) that
has the ability to bind duck hepatitis B virus particles [9,10]. Bovine CPD was independently
discovered in a search for an enzyme with carboxypeptidase E-like properties [11]. In all spe-
cies examined, CPD was found in all tissues examined, displaying a broad tissue distribution
[12–14]. Except for CPD, all other members of the M14B subfamily contain a single domain of
~300 amino acids with homology to CPA1 (and other enzymes in the M14A subfamily) fol-
lowed by ~80 amino acids with structural homology to transthyretin. In contrast, CPD from
mammals, birds, and Drosophila contain three of these carboxypeptidase/transthyretin-like
domains (Fig 1) [10,11,15,16].
The critical catalytic residues, metal-binding residues, and substrate-binding residues
found in all active members of the M14 gene family are conserved in CPD domains I and II
but not in domain III. CPD also contains a transmembrane segment of about 20 residues and
Fig 1. Linear representation of full-length human CPD and recombinant forms showing the location of single point
mutations. The positions indicated in human CPD correspond to key residues essential for the catalytic mechanism: His69,
Glu72, Arg145, His198, Tyr248, and Glu270 (according to the bCPA1 numbering). Sp, indicates the location of the endogenous
signal peptide on the N-terminus. Recombinant proteins correspond to C-terminal truncated forms of human CPD, which lack the
C-terminal transmembrane anchor and the cytoplasmic tail. The mutations (i.e., Glu to Gln) performed to generate single point
mutants for the CPD domain I (E350Q), domain II (E762Q) and a double mutant (E350Q/E762Q) are indicated. The black shaded
box on the N-term of the recombinant proteins corresponds to the IgM secretion signal sequence and N-terminal Strep-Tag II
fusion protein.
https://doi.org/10.1371/journal.pone.0187778.g001
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a C-terminal cytosolic tail of 60 residues (Fig 1). CPD is primarily localized in the trans-Golgi
network (TGN), and cycles between the TGN and the cell surface [17]. The 60-residue cyto-
solic tail has previously been shown to be both necessary and sufficient for the trafficking of
CPD, and sequences within this region have been found to bind cytosolic proteins (such as
protein phosphatase 2A) and mediate TGN retention and intracellular trafficking [18–20].
The three carboxypeptidase (CP) domains of CPD are localized to the lumen of the TGN,
exocytic vesicles, and endocytic vesicles, and are exposed to the extracellular environment
when the enzyme is transiently present on the cell surface [21]. Based on the broad tissue dis-
tribution of CPD, its subcellular localization, and ability to cleave basic residues from several
peptides that have been tested, CPD is thought to play a role in the further processing of pro-
teins and peptides that are initially cleaved by furin and furin-like enzymes within the secre-
tory pathway, on the cell surface, and within the endocytic pathway. Previous studies testing a
very small number of synthetic substrates found that duck and Drosophila CPD domains I and
II are enzymatically active, but the third domain of CPD is catalytically inactive toward tradi-
tional MCP substrates [16,22]. Duck and Drosophila CPD domain I are optimally active at
neutral pH and cleave a peptide with C-terminal arginine more efficiently than a similar pep-
tide with C-terminal lysine [16,22]. By contrast, CPD domain II is optimally active at slightly
acidic pH and cleaves a peptide with C-terminal lysine as efficiently as a peptide with C-termi-
nal arginine [9,16,22]. However, these previous studies tested only one peptide with C-termi-
nal Lys, and it was not clear if these results could be generalized to all Lys-containing peptides.
Sidyelyeva et al. investigated the function of the various CP domains through the analysis of
spontaneous mutations in the various domains and through the creation of flies expressing
specific forms of CPD in the svrPG33 mutant [23,24]. All mutants containing an active CP
domain rescued the lethality with varying degrees, in all cases requiring the presence of inac-
tive CPD domain III for full viability. Transgenic flies expressing active CPD domain I or
domain II showed similar behaviors to each other and to the viable svr mutants, suggesting
redundant functions in terms of processing peptides involved in viability and in behaviors like
cold and ethanol sensitivity, as well as long-term memory [24].
CPD has been implicated in several human diseases. In one study, CPD was found to be
downregulated in CD14 positive cells isolated from patients with lupus erythematosus [25]. In
a study using high-density oligonucleotide microarrays with colon biopsies, CPD was identi-
fied as one of seven discriminatory genes that could functionally classify patient samples as
adenoma, colorectal carcinomas or inflammatory bowel diseases [26]. CPD is frequently over-
expressed in human cancers such as hepatocellular carcinoma, with 164 of 400 samples show-
ing high expression of CPD; downregulation of CPD inhibited carcinoma cell proliferation
through induction of G1 cell-cycle arrest and apoptosis [27]. In a study of human prostate
specimens, CPD immunostaining was higher in cancer cells than in benign cells [28].
Despite the numerous studies finding CPD to be associated with human disease, the enzy-
matic properties of human CPD have not been studied in detail. The objective of the present
study was to investigate the properties of human CPD and functionally characterize its individ-
ual catalytic domains. For this, we generated catalytically inactive single point mutants for the
individual active domains I and II (E350Q, E762Q, respectively) as well as a double mutant
(Fig 1). We characterized the enzymatic properties of the full active human CPD and the indi-
vidual catalytically active domains, using a wide range of substrates and quantitative peptido-
mics approaches. We found that human CPD domain III is inactive towards all peptides
examined, while domains I and II have complementary activities that provide for a wider abil-
ity to cleave peptides/proteins with basic C-terminal residues within the secretory pathway, on
the cell surface, and within the endocytic pathway. However, not all peptides with C-terminal
basic residues were efficiently cleaved by domains I and/or II, indicating the importance of
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other residues within the peptide. Finally, we modeled the structure of all three domains of
hCPD and performed molecular docking experiments with a set of peptide substrates. Our
thorough characterization of the substrate specificities of the individual domains of human
CPD suggests the functional specialization of each CPD domain to distinct subcellular
environments.
Materials and methods
Cell culture
HEK293T cells (ATCC CRL-3216) were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with GlutaMAX and 10% (v/v) fetal bovine serum (Invitrogen, Inc.)
at 37˚C, 10% CO2 and 95% humidity. HEK293F cells (Free Style
TM 293-F Cells, Thermo-
Fischer Scientific) were grown in FreeStyle 293 Expression Medium (Invitrogen, Inc.) in flasks
on a rotary shaker (120 rpm) at 37˚C, 8% CO2 and 70% humidity.
Recombinant protein production and purification
Human carboxypeptidase D (residues 32–1298) was cloned into the pTriExTM-7 expression
vector (Merck Millipore) encoding for mouse IgM secretion signal sequence and an N-termi-
nal Strep-Tag II fusion protein. CPD E270Q mutants (according to bovine CPA1 numbering)
named here as E350Q, E762Q (for single mutants) and E350Q/E762Q (for the double mutant)
were generated by PCR-driven overlap extension [29]. For protein production in mammalian
cells, DNA transfections of CPD and the CPD E270Q mutants were carried out using 25-kDa
polyethylenimine (Polysciences) in a ratio of 1:3 (μg DNA/μg polyethylenimine), as described
previously [30]. Briefly, HEK293F cells were diluted to a cell density of about 0.5x106 cells/ml,
grown in FreeStyle 293 Expression Medium for 24 h and then transfected with 1 μg DNA per
ml of culture for 7 days. For protein purification, 500 ml of the culture supernatant were equili-
brated with 30% ammonium sulphate, centrifuged, filtered through 0.2 μm filters and bound
to a 15 ml hydrophobic chromatography column (Toyopearl Butyl-650M, Tosoh Bioscience).
Protein elution was carried out with a decreasing gradient of ammonium sulphate (30 to 0%)
in a 100 mM Tris-HCl, pH 7.5 buffer. The eluted fractions containing CPD (as analyzed by
SDS-PAGE) were pooled and loaded onto a 5 ml Strep-Tactin affinity column (IBA GmbH)
equilibrated with 5 column volumes (cv) binding buffer (100 mM Tris-HCl, pH 8.0, 150 mM
NaCl), washed with 2 cv of binding buffer and eluted with 8 cv of the elution buffer (i.e.,bind-
ing buffer containing 2.5 mM d-desthiobiotin; IBA GmbH). Eluted fractions were analyzed by
SDS-PAGE, and the purest fractions were pooled and loaded onto a HiLoad Superdex 75 26/
60 column (GE Healthcare) previously equilibrated with a 50 mM Tris-HCl, pH 7.5, 150 mM
NaCl buffer. The purified proteins were flash frozen at a concentration of approximately 0.5
mg/ml and stored at -80˚C.
HEK293T bortezomib treatment and peptide extraction
HEK293T cells were seeded in 24 150-mm cell culture plates and after growing up to 70% con-
fluence, cells were treated with fresh media containing 0.5 μM bortezomib for 1 h. Following
incubation, cells were washed three times with cold Dulbecco’s phosphate-buffered saline
(DPBS, Invitrogen) supplemented with 0.5 μM bortezomib, immediately scraped and centri-
fuged at 8000xg for 5 min. For peptide extraction, the cell pellet was resuspended in 1 ml of
80˚C water and the mixture was incubated for 20 min in an 80˚C water bath. Samples were
cooled, transferred to 2 ml low retention microfuge tubes and centrifuged at 13,000xg for 20
min. Soluble fractions containing HEK293T cell peptides were stored at -80˚C overnight.
Substrate specificity of human carboxypeptidase D
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Samples were centrifuged again and the supernatant of each tube was collected and concen-
trated in a vacuum centrifuge to a volume of 1.5 ml. Finally, samples were cooled and acidified
with 0.1 M HCl to get a final concentration of 10 mM HCl. After 15 minutes of incubation,
samples were centrifuged at 13000xg for 40 min at 4˚C and the supernatants stored at -80˚C
until labelling.
Preparation of tryptic peptide libraries
Tryptic peptide libraries were generated by digesting five different proteins with trypsin. Tryp-
sin is an endoprotease that cleaves C-terminal to arginine or lysine residues, producing pep-
tides containing basic residues on their C-termini [31]. The proteins bovine serum albumin
(BSA), bovine thryroglobulin, bovine α-lactalbumin, human α-hemoglobin and human β-
hemoglobin (all from Sigma-Aldrich) were digested separately and then pooled in order to
have a tryptic peptide library with a final peptide concentration of about 500 μM. To prepare
the tryptic peptide libraries, 5 nmoles of each protein were digested for 16 h at 37˚C in a 20
mM borate, pH 7.6 buffer using sequencing-grade trypsin (Promega) at an enzyme/substrate
ratio of 1/100 (w/w). The efficiency of protein digestion was checked by SDS-PAGE. To stop
the proteolytic digestion, 100 mM HCl was added to a final concentration of 1 mM. All the
reactions were combined and centrifuged at 13,000xg for 45 min at 4˚C. The supernatant con-
taining tryptic peptides was filtered through a 10-kDa centrifugal filter device (Amicon, Merck
Millipore), aliquoted and stored at -80˚C until use.
Kinetic measurements using fluorescent substrates
Carboxypeptidase activity was assayed with the fluorescent substrates dansyl-Phe-Ala-Arg,
dansyl-Phe-Gly-Arg or dansyl-Phe-Pro-Arg synthesized as described [32]. The assay was mod-
ified slightly from the previously described procedure. In brief, 0.2 mM of substrate was incu-
bated with enzyme at the indicated concentrations (see S1 Fig) for 60 min at 37˚C in 100 μl of
100 mM Tris-acetate (pH 6.4) containing 100 mM NaCl. Reactions were stopped by adding
50 μl of 500 mM HCl and 1 ml of chloroform. Tubes were mixed and centrifuged for 2 min at
300xg. After centrifugation, 0.5 ml of the chloroform phase was transferred to new tubes and
dried overnight at 25˚C in a fume hood. Dried samples were resuspended with 200 μl of PBS
containing 0.1% of Triton X-100. The amount of product generated was determined by mea-
suring the fluorescence emission of samples at 495 nm upon excitation at 350 nm using a
96-well plate spectrofluorometer. For kinetic analysis, purified enzymes (at different concen-
trations, i.e. 2.5 nM for the full-active enzyme; 5.0 nM for CPD E762Q; 20.0 nM for CPD
E350Q; and 100.0 nM for CPD E350Q/ E762Q were assayed at different substrate concentra-
tions (6.25, 12.5, 25, 50, 100, 200, 300 and 600 μM). In all cases, a maximum of 20% of the sub-
strate was hydrolyzed. Kinetic parameters were determined by fitting the obtained data for
each enzyme to the Michaelis-Menten equation (y = (Vmax x X) /(Km + X)) using GraphPad
Prism software [33], where X is the substrate concentration, Vmax is the maximum enzyme
velocity and Km is the Michaelis-Menten constant. The pH optimum of purified enzymes was
determined with 0.2 mM dansyl-Phe-Ala-Arg in 100 mM Tris-acetate, 150 mM NaCl buffer at
the indicated pH.
Peptidomics
Quantitative peptidomics experiments were performed as described previously [34,35], with
slight modifications. We used the peptide library generated using trypsin or by peptide extrac-
tion from HEK293T cells, as described above. The peptide mix was incubated for 16 h at 37˚C
in 100 mM borate, pH 6.5, 100 mM NaCl buffer with different amounts (0, 1, 10 and 100 nM)
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of purified rhCPD. In a second round of experiments, peptides from the peptide library gener-
ated with trypsin were incubated with rhCPD and with the CPD single point mutants (E350Q,
E762Q and E350Q/E762Q) at a concentration of 100 nM for 16 h at 37˚C. After incubation,
reactions were quenched and peptides were labeled using 4-trimethylammoniumbutyrate isoto-
pic tags activated with N-hydroxysuccinimide (TMAB-NHS) containing either all hydrogen
(D0), 3 deuteriums (D3), 6 deuteriums (D6), 9 deuteriums (D9), or 9 deuteriums and three
atoms of 13C (D12). The labels were dissolved in DMSO to a concentration of 0.4 mg/μl and 5
mg of label was used per sample. At the start of the experiment, the pH of the sample was
adjusted to 9.5 with 1M NaOH. Labeling was performed over 8 rounds; 1.6 μl of the label was
added to the extract every 20 min. The pH was measured between each round and if necessary,
brought back to 9.5, only for the first five rounds. After labeling, 30 μl of 2.5 M glycine was
added to quench any unreacted label. Labeled samples for a single experiment were pooled, fil-
tered through a10-kDa centrifugal filter device and 30 μl of 2M hydroxylamine was added to
hydrolyze any labeled tyrosines. This was done to ensure that only N-terminal amines and lysine
side-chain amines of peptides are TMAB-labeled and not tyrosines. Samples were desalted
through C-18 spin columns (Thermo-Scientific) by following the manufacturer’s instructions.
Peptides were eluted using 160 μl of 0.5% TFA and 70% acetonitrile, freeze-dried in a vacuum
centrifuge, and subjected to liquid chromatography and mass spectrometry as described [34,35].
Identifications were performed using Mascot software (Matrix Science). The MS spectra were
manually examined for peak sets reflecting peptides with the various isotopic forms of the
TMAB tags. Identifications were rejected unless 80% or more of the major fragments from the
MS/MS matched predicted b- or y-series fragments (with a minimum of five matches). Addi-
tional criteria followed to consider the matches includes the coincidence with the parent mass
within 50 ppm of the theoretical mass, an expected charge equal to basic residues plus the N-ter-
minus and a correct number of isotopic tags incorporated considering the number of free
amines present in the peptide. Peptidomics analyses were performed at least in triplicate.
Structural alignment, homology modeling and surface representations
The amino acid sequences of human CPD, as well as human CPM and bovine CPA were
obtained from the UniProt database (accession codes O75976, P14384 and P00730, respec-
tively). A structure-based sequence alignment between CPD domains I, II and III was gener-
ated using PROMALS3D multiple sequence and structure alignment server [36].
Structural models of the different human CPD domains were constructed using the Prime
Homology Modeling Workflow implemented in Schro¨dinger and further subjected to an
energy-based refinement to improve their quality [37,38]. The structure of duck CPD (PDB:
1H8L) was taken as a template, based on its higher sequence identity with the targets (i.e., 38%
SI with hCPD domain I; 79% SI with domain II and 31% SI with domain III) (See multiple
alignment from S3 Fig). Final models contained the catalytic zinc ion, which was transferred
from the 1H8L structure. Electrostatic potential calculations for the three domains, including
the zinc ion, were carried out using APBS (Adaptive Poisson-Boltzmann Solver) and the corre-
sponding molecular surface represented with PyMOL [39].
The substrate binding sites of the domains were further characterized with SiteMap [40] by
using a grid of points able to identify hydrophobic and hydrophilic regions, hydrogen bond
donor, hydrogen bond acceptor and metal-binding regions.
Peptide docking studies
The peptide docking was performed using the standard-precision docking protocol for pep-
tides from Glide [41]. Ten million poses were initially kept and 1,000 poses per ligand were
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used for energy minimization. The best 101 docking poses were subjected to full force-field
minimization, and these finally resulting poses were selected for further analysis. For the dock-
ing, we used the structure of zinc-containing form of the enzyme. However, for practical calcu-
lations, the zinc ion was not included during the flexible peptide docking search, given that the
empirical force-field used cannot fully describe all the complexities derived from the charge
delocalization of the zinc ion, due to its coordination with a water molecule as well as with His
and Glu side-chains in MCPs. Nevertheless, the zinc ion was included for visual inspection of
the results and in the calculation of the electrostatic and donor/acceptor maps. PyMOL [39]
was used for generation of figures.
Results
Recombinant protein production and purification
Several expression systems were explored to produce active recombinant CPD. Pichia pastoris
was previously used to produce CPD domain I and CPD domain II, as well as other members
of the M14 MCP family [34,42–44]. However, human CPD containing all three domains did
not express well in this system, possibly due to structural complexity and/or the numerous
post-translational modifications like N-linked glycosylation. Previous studies produced sub-
stantial levels of full-length CPD using the baculovirus expression system [9,22]. However,
there are fundamental differences in the glycoprotein processing pathways of insects and
higher eukaryotes, which lead to structural and functional differences between native and such
recombinantly produced proteins. Recently, mammalian-based expression systems have
emerged as promising systems to obtain high levels of complex mammalian proteins by tran-
sient or stable transfection [45,46]. For this reason, we cloned residues 32–1298 of human car-
boxypeptidase D (named here as rhCPD) into the pTriExTM-7 expression vector that encodes
an IgM secretion signal sequence and an N-terminal Strep-Tag II fusion protein (Fig 1). Resi-
dues 32–1298 of CPD encode the three carboxypeptidase-like domains and lack the C-terminal
transmembrane domain and cytosolic tail. The CPD-pTrieX-7 construct was transfected into
mammalian HEK293F cells for transient expression, using polyethylenimine as transfection
reagent. The secreted recombinant protein showed a major band of 170 kDa by western blot
analysis using an anti-Strep-tag II antibody, consistent with the predicted molecular weight for
rhCPD (data not shown). Maximum levels of soluble rhCPD in the medium were detected 7
days post-transfection.
A variety of conditions were tested to purify rhCPD from the medium, and optimal results
were obtained following a three-step chromatography protocol. The first chromatographic
step was a hydrophobic interaction chromatography. The eluates containing the rhCPD pro-
tein from the first purification step were pooled and purified over an anti-Strep-tag affinity
resin and, further fractionated on a size exclusion column (Fig 2A) to obtain a high-purity
protein product (Fig 2B). To characterize the substrate specificity of the individual catalytic
domains we generated constructs with single point mutations in domains I or II as well as a
double mutant, named here as E350Q, E762Q and E350Q/E762Q, respectively (Fig 1). All
mutants were expressed and purified following the protocol optimized for rhCPD (Fig 2B). In
gel filtration chromatography, all mutants eluted in a single peak with comparable apparent
masses (data not shown).
Effect of pH on CPD activity
The influence of pH on rhCPD and rhCPD single point mutants were examined using the
fluorescent substrate dansyl-Phe-Ala-Arg. The pH optimum of the human protein with both
domains I and II active is 6.5, with>50% maximal activity from 5.0–7.5 (Fig 3A). The
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construct E350Q shows optimal activity at pH 6.5, with activity >50% of the maximum over
the range 5.0–7.5, while the construct E762Q has optimal activity at pH 7.0 and with>50%
maximal activity over the range 6.5–7.5 (Fig 3B). The double mutant E350Q/E762Q had no
detectable enzyme activity at any of the pH values examined (Fig 3B).
Activity of CPD and CPD single point mutants with fluorescent
substrates
The enzymatic activities of rhCPD were tested with three fluorescent synthetic substrates. To
compare substrates, different amounts of the purified enzyme were incubated with 200 μM of
each dansylated peptide and the relative amount of product determined. Among the substrates
evaluated, dansyl-Phe-Ala-Arg was the peptide most rapidly cleaved by rhCPD (S1 Fig); at
enzyme concentrations where 70% of dansyl-Phe-Ala-Arg was cleaved, less than 5% of dansyl-
Phe-Gly-Arg was hydrolyzed by the enzyme. No activity was detected towards the substrate
with a Pro residue in penultimate position (i.e., dansyl-Phe-Pro-Arg). We determined the
kinetic parameters for dansyl-Phe-Ala-Arg for the full active rhCPD and the single point
mutants E350Q and E762Q (Table 1). These studies were conducted at pH 6.5 because all three
proteins showed80% maximal activity at this pH value. The kcat value of the E350Q mutant
with only domain II active (7.0 ± 0.9 s-1) is generally comparable to the kcat of the E762Q mutant
with domain I active (8.5 ± 0.5 s-1) and both are smaller than the kcat for rhCPD with both active
Fig 2. Expression and purification of CPD. (A) Schematic diagram of the strategy for expression and purification of rhCPD and
mutants. Protein expression was performed by transient transfection of suspension-growing HEK293F cells. Extracellular medium
was collected after 7 days incubation, followed by purification of the recombinant proteins in three steps; (1) hydrophobic interaction
chromatography using a Butyl 650-M, (2) affinity chromatography using anti-Strep-tag resin, and (3) gel filtration chromatography. (B)
Coomassie-stained SDS–PAGE showing the purity of recombinant CPD proteins.
https://doi.org/10.1371/journal.pone.0187778.g002
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domains (12.5 ± 0.5 s-1). The lowest Km value was obtained for the full active rhCPD, which
showed a Km of 153 ± 16 μM, while single point mutants E762Q and E350Q showed higher
Km values of 319 ± 37 μM and 844 ± 139 μM, respectively. The kcat/Km value for rhCPD was
Fig 3. Effect of pH on the activity of different recombinant CPD forms. (A) Effect of pH on rhCPD and (B)
single point mutants using 200 μM dansyl-Phe-Ala-Arg in a Tris-acetate buffer at the indicated pH for 60 min
at 37˚C. The activity represented is the average of three independent measures with less than a 10% of
variation, expressed as a percentage of the maximal activity, observed at optimal pH.
https://doi.org/10.1371/journal.pone.0187778.g003
Table 1. Kinetic constants for hydrolysis of dansyl-Phe-Ala-Arg by rhCPD and rhCPD single point mutants.
Substrate rhCPD Active domain I rhCPD (E762Q) Active domain II rhCPD (E350Q) Double mutant rhCPD (E762Q /E350Q)
Dansyl-Phe-Ala-Arg
km (μM) 153 ± 16 319 ± 37 844 ± 139 ND
kcat (s-1) 12.5 ± 0.5 8.5 ± 0.5 7.0 ± 0.9 ND
kcat/ Km (μM-1 s-1) 0.082 ± 0.012 0.027 ± 0.003 0.008 ± 0.001 ND
ND, not detectable; Data are shown as mean of three independent experiments (n = 3) ± SE
https://doi.org/10.1371/journal.pone.0187778.t001
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approximately 3 times and 10 times higher in comparison with values obtained for the E762Q
and E350Q single point mutants, respectively (Table 1).
Characterization of the substrate specificity of full active human CPD by
quantitative peptidomics
The results obtained using synthetic substrates are useful, but is limited by the availability of
substrates. To gain more information about the substrate specificity with a wide range of pep-
tides, we used a quantitative peptidomic approach to address the substrate specificity of
human CPD and unravel the contributions of each individual active domain. Quantitative
peptidomics allows the study of proteolytic activity by analysing a large number of peptide sub-
strates in a single experiment, thereby providing a more complete understanding of MCP sub-
strate specificities [34,35,47,48]. First, to characterize the substrate specificity of the full active
protein, we performed a peptidomics experiment in which different amounts of purified
rhCPD (ranging from 0 to 100 nM) were incubated with a peptide mixture obtained by diges-
tion of selected proteins with trypsin (see Materials and Methods section for more details).
This tryptic peptide library contains mainly peptides with basic residues (Arg or Lys) on their
C-termini, and only a small number of peptides lacking C-terminal basic residues which arose
from either the C-terminus of the proteins or from non-tryptic cleavages. After incubation of
aliquots of the peptide library with the indicated amount of CPD, the individual reactions
were each labeled with a different isotopic TMAB tag, combined and analyzed by liquid chro-
matography/mass spectrometry (LC-MS) (see experimental scheme and representative data in
Fig 4).
Over 55 peptides were identified by tandem mass spectrometry (MS/MS) and/or close
matches with the theoretical mass of the peptides generated with trypsin. Some of these pep-
tides exhibited a peak set with roughly equal peak heights, revealing that these peptides were
not substrates or products of rhCPD under the experimental conditions used (Fig 4B and S1
Table). Some peptides were extensively cleaved, showing a complete or almost complete
decrease in the peak intensity (60%) in the sample incubated with the highest concentration
of enzyme (i.e., 100 nM) and a partial decrease in the peak intensity of the sample incubated
with a lower concentration of rhCPD (i.e., 10 nM); these are considered as good substrates of
rhCPD (Fig 4C and Table 2). In addition, some peptides were only partially cleaved (decrease
in the peak intensity20% and<60%), exhibiting a small decrease in intensity with the high-
est concentration of enzyme assayed, and no major decrease in the peak intensity with the con-
centration of 10 nM; these are considered as weak substrates of rhCPD (Fig 4D and S2 Table).
Some peptides showed an increase in peak intensities that correlated with the amount of
rhCPD. In all cases, the peptides that increased upon incubation with CPD lacked C-terminal
basic amino acids and are products of rhCPD cleavage (Fig 4E and S3 Table). Based on the
location of the peptide within the protein and the downstream sequence, we deduced the resi-
due that was cleaved (see cleaved aa in S3 Table).
The majority of peptides with C-terminal (P1’) Lys were either good or weak substrates of
rhCPD, while fewer of the peptides with C-terminal Arg were good substrates and the majority
of these peptides were non-substrates (Fig 5A and S1 Table). Further, the influence of the
penultimate (P1) residue on rhCPD substrates and non-substrates was examined (Fig 5B). For
this analysis, only peptides with permissive C-terminal residues (Lys or Arg) were considered.
Good substrates of rhCPD contained Ala, Ser, Phe, Leu, Lys, Thr, or Glu in the P1 position
(Fig 5B and Table 2). Weak substrates contained C-terminal Thr, Ser, Leu, Gly, Val, Glu, Asn
or Gln (S2 Table). From these analyses, three products of rhCPD were detected; these peptides
were generated by cleavage of peptides containing Arg or Lys at the C-termini and Ala, Phe or
Substrate specificity of human carboxypeptidase D
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Thr in the P1 position (S3 Table). Finally, it is noteworthy to mention that no peptide with
Pro, Asp, or Ile in the P1 position ws identified as a rhCPD substrate. Some of these peptides
Fig 4. Quantitative peptidomics scheme for the characterization of rhCPD substrate specificity using the tryptic
peptide library and representative spectra. (A) Quantitative peptidomics scheme. Tryptic peptides were obtained
from digestion of five selected proteins (BSA, bovine thyroglobulin, bovine α-lactalbumin and human α and β–
hemoglobin) with trypsin. The resultant peptide library was aliquoted and digested with no enzyme or different rhCPD
concentrations of 0.1, 1, 10, and 100 nM for 16 h at 37˚C. After incubation samples were labeled with one of five stable
isotopic TMAB-NHS tags (D0 = 100 nM; D3 = 10 nM; D6 = 1 nM; D9 = 0.1 nM; D12 = No enzyme). Then, samples were
pooled and analyzed by LC-MS. Examples of representative data are shown for (B) non-substrates, (C) good substrates,
(D) weak substrates and (E) products.
https://doi.org/10.1371/journal.pone.0187778.g004
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contained C-terminal basic residues (including Arg and Lys), which suggest an important neg-
ative influence of these residues on the CPD activity when they are found in P1 position.
During the peptidomic analysis, peptides containing Cys, Tyr, or His showed variable peak
intensities that did not correlate with the amount of CPD. In addition, peptides containing
cyanoCys, mono-iodoTyr, di-iodoTyr, mono-iodoHis, and di-iodoHis were identified from
MS/MS analysis of the data; these peptides result from chemical reactions due to impurities in
the TMAB labels [49]. This finding might explain the absence and/or relatively low abundance
of peptides with Cys, Tyr, or His residues in some previous peptidomics studies which used
TMAB tags [34,35,47–50]. Consequently, peptides with Tyr, His, or Cys were not considered
for the present work.
Characterization of the substrate specificity of human CPD domains I
and II by quantitative peptidomics
To gain insight into the substrate specificity of the domains I and II of human CPD, we
repeated the quantitative peptidomics and compared rhCPD with the various mutant forms in
a single LC/MS run. A schematic of one experiment and labeling strategy is shown in Fig 6A;
we performed at least three biological replicates of each enzyme form. For this analysis, a single
concentration (100 nM) of purified rhCPD, of single point mutants E350Q and E762Q, and
the double mutant E350Q/E762Q were incubated with the same tryptic peptide library used
for the characterization of rhCPD described above. After incubation with the enzyme, the indi-
vidual reactions were differentially labeled with isotopic TMAB tags, combined and subjected
to LC-MS analysis (Fig 6A).
Over 48 peptides were identified through tandem mass spectrometry (MS/MS) and/or by
close matching with the theoretical mass of the peptides generated with trypsin. After the
Table 2. Good substrates of rhCPD identified using the tryptic peptide library.
Protein precursor Peptide sequence Z T Obs M Theor M ppm Ratio of peak intensity
rhCPD / No enzyme
100 nM 10 nM 1 nM 0.1 nM
Thyroglobulin QQAAALAK 2 2 799.46 799.46 -4 <0.10 0.68 0.95 1.08
Thyroglobulin FPLGESFLAAK 2 2 1178.64 1178.63 12 <0.10 0.94 1.12 1.09
α-Hemoglobin VDPVNFK 2 2 817.43 817.43 2 <0.10 0.87 1.03 1.06
Thyroglobulin GQEFTITGQKR 3 2 1263.67 1263.66 11 <0.10 0.75 0.96 0.95
Bovine serum albumin ADLAK 2 2 516.28 516.29 -14 0.11 0.83 1.0 1.11
Thyroglobulin KFEK 2 3 550.29 550.31 -38 0.11 0.67 0.85 1.07
Thyroglobulin SLSLK 2 2 546.33 546.34 -15 0.13 0.89 0.98 1.13
Thyroglobulin LPESK 2 2 572.32 572.32 -8 0.14 0.64 0.49 1.07
Thyroglobulin KFEKLPESK 2 4 1104.61 1104.62 -5 0.15 0.66 0.96 1.19
Thyroglobulin LTDEELAFPPLSPSR 2 1 1670.88 1670.85 20 0.16 0.78 1.10 1.07
Bovine serum albumin LVNELTEFAK 2 2 1162.63 1162.62 12 0.20 0.94 1.09 1.09
α-Hemoglobin LRVDPVNFK 3 2 1086.63 1086.62 13 0.21 0.88 1.09 1.06
Bovine serum albumin LVTDLTK 2 2 788.47 788.46 9 0.40 0.84 1.05 1.08
Good substrates, peptides affected with a decrease60% by the highest concentration of enzyme. Z, charge; T, number of isotopic tags incorporated into
each peptide; Obs M, observed monoisotopic mass; Theor M, theoretical monoisotopic mass; ppm, difference between Obs M and Theor M (in parts per
million); Peak intensity ratio rhCPD/no enzyme, the ratio in peak intensity between the sample incubated with enzyme and the sample incubated without
enzyme. 100 nM, 10 nM, 1 nM and 0.1 nM refer to rhCPD concentration; When the peak intensity was below the background, the ratio is expressed as
<0.10.
https://doi.org/10.1371/journal.pone.0187778.t002
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analysis, the results revealed some peptides which showed roughly equal peak heights; these
peptides were considered to be neither substrates nor products under the assay conditions
used (S4 Table). Some peptides were cleaved by the enzyme with both domains I and II active,
showing a complete or almost complete decrease in the peak intensity upon incubation with
Fig 5. Analysis of the substrate preferences of rhCPD using the tryptic peptide library. (A) Substrate preferences
of rhCPD at C-terminal (P1’) and (B) P1 positions. The number of times each amino acid was present in P1 or P1’ was
determined for good substrates, weak substrates and non-substrates and represented. For P1 analysis, only substrates
with permissive P1’ residues (Lys or Arg) were considered.
https://doi.org/10.1371/journal.pone.0187778.g005
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rhCPD; these are considered as substrates (which include good and weak substrates) of rhCPD
(Fig 6B and Table 3). Among them, some peptides showed a complete or almost complete
decrease in the peak intensity after incubation with either single point mutant E350Q or
Fig 6. Quantitative peptidomics scheme for the substrate characterization of CPD domains I and II using a
tryptic peptide library and representative spectra. (A) Quantitative peptidomics scheme. Tryptic peptides were
obtained as described above. The resultant peptide library was aliquoted and digested with 100 nM rhCPD, 100 nM
rhCPD E350Q, 100 nM rhCPD E762Q or 100 nM rhCPD E350Q/E762Q for 16 h at 37˚C. Then, samples were labeled
with one of the isotopic TMAB-NHS tags. For the representative data shown in this figure, D3 = rhCPD; D6 = rhCPD
E762Q; D9 = rhCPD E350Q; and D12 = rhCPD E350Q/E762Q. Finally, samples were pooled and analyzed by LC-MS.
Examples of representative data are shown for (B) good substrates of both domains I and II, (C) preferential substrates
of domain II and (D) preferential substrates of domain I. The entire experiment was performed three times and the
various enzyme digests were labelled with different tags to control for variability of the individual reagents.
https://doi.org/10.1371/journal.pone.0187778.g006
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E762Q (Fig 6B and Table 3); these are considered as substrates of both domains. However,
some peptides substrates of rhCPD revealed a complete or almost complete decrease in the
peak intensity upon incubation with the single point mutant E350Q and a slight or no decrease
in the peak intensity upon incubation with E762Q; these are considered as preferential sub-
strates of domain II (Fig 6C and Table 3). Another group of peptides revealed a moderate
decrease in the peak intensity upon incubation with the single point mutant E762Q and a
slight or no decrease in the peak intensity upon incubation with the E350Q mutant; these are
considered as preferential substrates of domain I (Fig 6D and Table 3).
Analysis of the P1’ residue of substrates of domain I showed a predominance of Arg, with
11 substrates containing C-terminal Arg and only 2 substrates containing C-terminal Lys (Fig
7A). In contrast, substrates of domain II were more evenly divided between C-terminal Lys
versus Arg (Fig 7C). Peptides with C-terminal Arg and Lys were also identified as non-sub-
strates of the mutant CPD with single catalytic domains. For these peptides, the identity of the
penultimate (P1) residue was further analyzed (Fig 7B and 7D). Good substrates of the CPD
Table 3. Good and weak substrates identified within substrate characterization of CPD domains I and II using the tryptic peptide library.
Protein precursor Peptide sequence Z T Obs M Theor M Ppm Ratio of peak intensity enzyme /
Control
Ratio of peak intensity dI active /
d II active
rhCPD Domain I
active
Domain II
active
Thyroglobulin GQEFTITGQKR 2 2 1263.66 1263.66 4 <0.10 <0.10 0.16 <0.10
α-Hemoglobin VDPVNFK 2 2 817.42 817.43 -20 <0.10 1.05 <0.10 >5.00
Thyroglobulin FAATSFR 2 1 798.40 798.40 -3 0.12 <0.10 0.24 <0.10
Bovine serum
albumin
LVNELTEFAK 2 2 1162.62 1162.62 1 0.27 0.65 <0.10 >5.00
Bovine serum
albumin
LVTDLTK 2 2 788.45 788.46 -16 0.33 0.83 0.29 3.53
α-Hemoglobin LRVDPVNFK 3 2 1086.57 1086.62 -44 0.34 1.09 <0.10 >5.00
Bovine serum
albumin
KQTALVELLK 3 3 1141.66 1141.71 -41 0.42 1.09 0.42 2.60
Bovine serum
albumin
AEFVEVTK 2 2 921.48 921.48 0 0.43 0.75 0.41 1.84
Thyroglobulin KVVLQDR 2 2 856.49 856.51 -18 0.54 0.52 0.66 0.86
Thyroglobulin AFLGTVR 2 1 762.44 762.44 5 0.59 0.56 0.53 1.07
Bovine serum
albumin
KVPQVSTPTLVEVSR 3 2 1639.00 1638.93 41 0.59 0.96 0.51 1.86
Thyroglobulin VVLQDR 2 1 728.42 728.42 0 0.64 0.79 0.79 1.00
Thyroglobulin AVKQFEESQGR 3 2 1277.64 1277.64 3 0.64 0.75 0.75 1.00
Thyroglobulin AISVPEDIAR 2 1 1069.63 1069.58 46 0.65 0.69 0.59 1.18
Thyroglobulin ASGLGAAAGQR 2 1 957.52 957.50 17 0.72 0.56 0.83 0.67
Thyroglobulin GQEIPGTR 2 1 856.47 856.44 33 0.72 0.59 0.59 1.00
Bovine serum
albumin
IETMR 2 1 648.31 648.33 -26 0.74 0.59 0.74 0.80
Thyroglobulin ELSVLLPNR 2 1 1039.64 1039.60 43 0.74 0.78 0.78 1.00
Thyroglobulin KGQEFTITGQK 3 3 1235.63 1235.65 -15 0.78 0.99 0.74 1.33
Good substrates, peptides affected with a decrease60% by rhCPD. Weak substrates, peptides affected with a decrease20% and <60% by rhCPD.
Ratio of peak intensity enzyme/control, the ratio in peak intensity between the sample incubated with rhCPD, E762Q or E350Q (as indicated for rhCPD,
domain I active or domain II active, respectively) and the sample incubated with the double mutant (E350Q/E762Q). Ratio of peak intensity d I active /d II
active, the ratio in peak intensity between the sample incubated with E762Q and the sample incubated with E350Q. See Table 2 for the rest of abbreviation
definitions.
https://doi.org/10.1371/journal.pone.0187778.t003
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domain I contained only Lys or Phe amino acids in this position. Weak substrates of CPD
domain I contained Ala, Thr, Asp, Val, Met, Asn, Gln or Gly in the P1 position (Fig 7B). Good
substrates of the CPD domain II contained Phe, Lys, Ala or Thr in the P1 position. Weak sub-
strates of the CPD domain II contained Asp, Thr, Ala, Leu, Ser, Met, Val, Asn, Gln or Gly in
this position (Fig 7D). Again, no peptides with Pro, Ile, or Glu in the P1 position were identi-
fied as substrates of either domain under the experimental conditions performed.
Six peptides were identified as products of rhCPD and the domain II only active mutant;
these resulted from cleavage of Arg or Lys from tryptic peptides, with Ser, Phe or Val at the P1
position of the cleavage site (S5 Table). Three of these peptides required removal of C-terminal
Arg, and these were also products of domain I. The other three peptides required removal of
C-terminal Lys, and two of these peptides were only products of domain II and not domain I.
The peptide LRVDPVNF was greatly elevated upon incubation with CPD with active domain
II, and slightly elevated by incubation with CPD with active domain I (S5 Table). Because the
corresponding tryptic peptide contains a Lys on the C-terminus, this finding shows that CPD
domain I is capable of cleaving C-terminal Lys, although not as efficiently as CPD domain II
cleaves C-terminal Lys from this peptide.
Human CPD cleaves exclusively C-terminal basic residues
The tryptic peptide library provided a large number of peptides with C-terminal basic residues,
but few peptides without C-terminal basic residues. To determine if rhCPD was able to cleave
any peptide lacking C-terminal basic residues, we performed a third quantitative peptidomics
study testing peptides extracted from HEK293T cells treated with bortezomib, a proteasome
Fig 7. Analysis of the substrate preferences of CPD domains I and II using a tryptic peptide library. (A,B) Substrate preferences of CPD
domain I (i.e., rhCPD E762Q). (A) C-terminal P1’ position preferences. (B) P1 position preferences. (C,D) Substrate preferences of CPD domain II
(i.e., rhCPD E350Q). (C) C-terminal P1’ position preferences. (D) P1 position preferences. The number of times each amino acid was present in P1
or P1’ was determined for good substrates, weak substrates and non-substrates. For P1 analysis, only substrates with permissive P1’ residues
(Lys, Arg) were considered.
https://doi.org/10.1371/journal.pone.0187778.g007
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inhibitor that causes an increase in the levels of many intracellular peptides [51]. After incuba-
tion of the peptides with CPD, the individual reactions were differentially labeled with isotopic
TMAB tags, combined and analyzed by LC-MS (see experimental scheme in Fig 8A).
Fig 8. Quantitative peptidomics scheme for the study of rhCPD substrate specificity using HEK293T derived
peptide library and representative spectra. (A) Quantitative peptidomics scheme. Peptides were extracted from
HEK293T cell cultures treated for 1 h at 37˚C with 0.5 μM bortezomib. The resultant peptide extract (i.e., HEK293T
peptidome) was aliquoted and digested with no enzyme or different rhCPD concentrations (i.e., 0.1, 1, 10, and 100 nM
at 37˚C for 16 h). After incubation samples were labeled with one of five stable isotopic TMAB-NHS tags (D0 = No
enzyme; D3 = 1 nM; D6 = 10 nM; D9 = 100 nM; and D12 = 0.1 nM). Then, samples were pooled and analyzed by
LC-MS. Examples of representative data are shown for (B) non-substrates, (C) good substrates, (D) weak substrates
and (E) products.
https://doi.org/10.1371/journal.pone.0187778.g008
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More than 60 peptides were identified through tandem mass spectrometry (MS/MS).
Unlike the tryptic peptide library, in the HEK293T derived library the majority of peptides
identified did not contain C-terminal basic residues. Nevertheless, none of these non-basic
ending peptides was affected by the treatment with rhCPD, and thus exhibited a peak set with
roughly equal peak heights (Fig 8B and S6 Table). Of the peptides that contained C-terminal
basic residues, some were extensively cleaved, showing a complete or almost complete decrease
in the peak intensity upon incubation with the highest concentration of enzyme of 100 nM
and a partial decrease in the peak intensity with a lower concentration of 10 nM; these are con-
sidered as good substrates of rhCPD (Fig 8C and Table 4). Some peptides were only partially
cleaved, exhibiting a small decrease in intensity with the highest concentration of enzyme
assayed and no or slight decrease in the peak intensity with the concentration of 10 nM; these
are considered as weak substrates of rhCPD (Fig 8D and S7 Table). A small number of pep-
tides showed an increase in the peak intensities related with increasing amounts of rhCPD;
these are considered as products resultant after the rhCPD cleavage (Fig 8D and S8 Table). As
expected, analysis of the P1’ residue showed again an exclusive preference for basic residues at
this position (Fig 9).
Comparative modeling of the active sites of human CPD domains I, II
and III
To date, a number of crystallographic studies have delimited the active site residues that play a
role in the catalytic mechanism of the M14B subfamily of MCPs [43,44,52–54]. As the three-
dimensional structures of human CPD domains are not yet available, we modeled all three
human domains based on the structures of duck and Drosophila melanogaster CPD domains
previously solved by our groups [43,44]. These models allow for the analysis of the structural
elements that contribute to CPD substrate preferences and biological activity.
The derived models of human CPD domains display active site clefts that are located at the
edge of the active-sites grooves within the β-sheet of the catalytic moiety, in agreement with
other MCP structures. Inside the catalytic cleft is found the typical catalytic zinc metal ion,
which is coordinated with one Glu and to two His residues. The basis of the active-site groove
is formed by strands β5, β6, β8 and the N-terminal part of helix α2. The wall of the groove fun-
nel is essentially defined by two projections of the α4–α5 multiple turn and by the α7–β7 hair-
pin loop, as described previously [43,44,52–54]. Fig 10 (panels A-C) shows the electrostatic
potential molecular surfaces of the catalytic sites of CPD domains I, II and III, highlighting the
Table 4. Good substrates of rhCPD identified using HEK293T peptides.
Precursor Sequence Z T Obs M Theor M ppm Ratio of peak intensity
rhCPD / No enzyme
100 nM 10 nM 1 nM 0.1 nM
Eukaryotic translation initiation factor 5A SAMTEEAAVAIKAMAK 3 3 1620.84 1620.821 11 <0.10 0.98 1.02 0.90
Acidic nuclear phosphoprotein pp32 STIEPLKK 3 3 914.53 914.54 -20 <0.10 1.12 1.15 1.00
40S Ribosomal protein S21 KADGIVSK 3 3 816.45 816.470 -20 <0.10 0.83 0.89 0.96
Histidine triad nucleotide-binding protein 1 Ac-ADEIAKAQVAR 2 1 1212.67 1212.646 21 0.15 1.03 1.03 1.14
Vimentin AELEQLKGQGKSR 3 3 1442.78 1442.78 0 0.23 0.95 0.97 1.11
Eukaryotic translation initiation factor 5A SAMoxTEEAAVAIKAMAK 3 3 1636.83 1636.821 3 0.32 0.98 1.00 0.94
Eukaryotic translation initiation factor 5A NMDVPNIKR 3 2 1085.57 1085.565 4 0.38 0.95 1.05 0.72
Hematological and neurol. exp. 1 prot. Ac-TTTTTFKGVDPNSRNSSR 3 1 2010.02 2009.977 20 0.40 1.13 1.07 0.97
See Tables 2 and 3 for abbreviation definitions
https://doi.org/10.1371/journal.pone.0187778.t004
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differences in electrostatic properties for the three domains. While domain I and II are more
similar in terms of electrostatic potential, the active site of domain III completely differs in the
distribution of its electrostatic surface potential. In addition, a characterization of the acceptor
maps (S2 Fig, panels A-C) and donor maps (S2 Fig, panels D-F) for these three domains
shows that they differ mainly in the properties of the S1’ and S1 region. Domain I has a more
clear preference for donor groups in S1 region, due to the acidic properties of some of the resi-
dues involved in this site (Asp312, Asp314 and Glu315), as compared with domain II (equiva-
lent residues in S1 region are Tyr724, Asn726 and Glu727). This observation is also reflected
in the electrostatic potential maps.
As shown in the multiple sequence alignment in S3 Fig, both domains I and II conserve
the three protein ligands of the catalytic zinc ion (His69, Glu72 and His196, based on the con-
ventional numbering system for the active form of bovine CPA1) and the residues directly
involved in catalysis (Arg127, Arg145 and Glu270, according to the bovine CPA1 numbering).
Further, CPD domains I and II display the same residues involved in the S1’ substrate binding
subsite (i.e., Asp and Gln residues in equivalent positions to 207 and 255 in bovine CPA1,
respectively), determining a substrate specificity for basic residues. Nonetheless, human CPD
domains I and II differ in some residues within the S1’ specificity pocket. One of the major dif-
ferences is that human CPD domain I contains Ser264 in a position comparable to Leu203 of
bovine CPA1 and Ser198 of CPM (S3 Fig), whereas CPD domain II contains Asn678 in an
equivalent position. Relevant residues at the S1 subsite, such as Tyr248 and Ser199 (following
the bovine CPA1 numeration) are essentially conserved between both CPD domains I and II,
whereas notable residue variations are observed in one of the loops (α7–β7 hairpin loop) that
shapes the border of the funnel and S1 subsite (see S3 Fig). The equivalent loop in CPM struc-
ture has been proposed to play an important role to accommodate the long hydrophobic P1
side chain of bradykinin [52].
Fig 9. Analysis of the P1’ substrate preferences of rhCPD using a HEK293T derived peptidomics library. The
number of times each amino acid was present in P1’ was determined for good substrates, weak substrates and non-
substrates.
https://doi.org/10.1371/journal.pone.0187778.g009
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Unlike domains I and II, human CPD domain III lacks the majority of key residues for CP
catalysis (S3 Fig). In this domain, only the first His residue involved in zinc binding (i.e.,
His69, according to the bovine CPA1 numeration) is present; in contrast, the other two resi-
dues involved in metal binding (i.e., Glu72 and His196, following bovine CPA1 numeration)
are replaced by Ala and Asp residues, a change conserved in duck CPD domain III [54]. While
Asp can coordinate zinc, Ala is not able to perform such function. Further, in the human
domain III, two residues involved in the catalytic mechanism (i.e., Glu270 and Arg127, accord-
ing to bovine CPA1 numeration) are occupied by Tyr and Gln, respectively. Residues Asn144,
Arg145 and Asn146 in bovine CPA1, responsible for the anchoring of the carboxylate group of
the substrate, are replaced by a triad of Asp, Thr and Asp in human CPD domain III. Interest-
ingly, the enzyme γ-D-glutamyl-(L)-meso-diaminopimelate peptidase I, which is a member of
the M14B subfamily of MCP and a distant relative of CPD, has a triad of Asn, Asp and Gln in
homologous positions to the triad Asn144/Arg145/Asn146. Such residue replacement confers
to this bacterial enzyme a particular substrate specificity for C-terminal meso-diaminopimelic
acid [6,55].
Fig 10. Structural modeling of the active sites of CPD domains I, II and III. Electrostatic potential molecular surfaces
of the catalytic sites of CPD domains I (A), II (B) and III (C) in presence of a modeled peptide. Lower panels show the best
docking pose based on GlideScore for the truncated peptide GQKR (green sticks) within the active sites of domains I (D),
II (E), and III (F), with the two last N-terminal residues omitted for clarity. Zn coordinates (yellow sphere) are added from
the template structure used for modeling (PDB 1H8L). Hydrogen bonds are depicted in black dashed lines, π-cation
interactions in pink and metal coordination in orange dashed lines. Within lower panels, the side chains of residues
directly involved in the zinc binding are shown (i.e., His69, Glu72 and His196 using bCPA1 numbering; corresponding to
His139/564, Glu142/567, and His257/671 in CPD domains I/ II), as well as the catalytic residue Glu270 (Glu350/762 in
CPD domains I/II). In addition, the side chains of some of the putative residues determining respectively the S1’ and S1
specificity pockets are shown for domains I/ I; i.e., Arg218/635 (corresponding to Arg145 of bCPA1 numbering); Tyr328/
740 (Tyr248 of bCPA1); and Gln335/747 (Ile255 of bCPA1). See S3 Fig for other residue equivalences.
https://doi.org/10.1371/journal.pone.0187778.g010
Substrate specificity of human carboxypeptidase D
PLOS ONE | https://doi.org/10.1371/journal.pone.0187778 November 13, 2017 20 / 29
In order to understand the detailed interactions between the peptides substrates within the
catalytic sites of the different CPD domains, we performed a preliminary docking experiment
with the GQEFTITGQKR peptide, which shows the highest preference for both active domains
(See Table 2 and Table 3). For the sake of simplicity, we used a truncated version of the pep-
tide; i.e., the tetrapeptide GQKR. The best docking pose for GQKR in domain I shows that the
C-terminal residue, arginine, interacts with the S1’ region formed by Asp268, Gln335 and
Ser264 (Fig 10A and 10D and S4 Fig). As expected from homologous systems, the terminal
carboxylate group interacts with the substrate-binding residues Arg218 and Asn217, while the
peptide bond subjected to cleavage is located near Arg208. The Zn ion and the main catalytic
residue, Glu350, are also surrounding this peptide bond. On the other hand, the lysine at P1
position, places the side chain in the previously described S1 region, interacting with the acidic
residues Asp312, Asp314 and Glu315 located at the α7–β7 hairpin loop (Fig 10A). In fact, the
S1 region displays a marked negative surface electrostatic potential that may explain its prefer-
ence for basic residues in P1 position. In the case of domain II, GQKR binding mode shows
similar interactions for the S1’ region, establishing contacts with Asp682 and Gln747 (Fig 10B
and 10E and S4 Fig). Residues Arg635 and Asn634 are stabilizing the C-terminal group, while
Arg625, Zn and Glu762 interact with the peptide bond. The lysine at the P1 position in the
peptide also interacts with the S1 region, but the type of interactions differ from those of
domain I. The positive charge of the lysine makes a π-cation interaction with Tyr724 as well as
hydrogen bond contacts with Glu727. In summary, although the binding mode of the tetra-
peptide is well reproduced in the two domains, differences in regions S1 and S1’ may explain
the differences in substrate specificity.
As previously explained, the active site of domain III lacks the main catalytic residues, thus
being unable to cleave conventional CP substrates. As the function of this domain remains
unknown, we wanted to assess its ability to accommodate peptides in its active site. Docking
studies with the truncated peptide GQRK predict that this domain is able to bind the peptide
with a similar binding mode (Fig 10C and 10F). The arginine in the C-terminal end interacts
strongly with Asp1107, which corresponds to Asp268 and Asp682 in domains I and II, respec-
tively. There is an additional interaction with Asp1064. Lysine in position P1 interacts with
Asp1145 and Glu1146, the latter being conserved in the three domains. However, there are some
differences in the rest of the residues that form the S1 region. In particular, Asp312 from domain
I is aligned to Tyr724 in domain II and Lys1143 in domain III. The properties of these three resi-
dues are different enough and may explain the different affinity of the domains for substrates.
Accordingly, these results support the hypothesis that domain III might be able to bind peptides
and may perform a non-enzymatic function, such as peptide binding and/or transport.
Molecular docking can help to explain substrate specificity of human
CPD domains I and II
In order to fully explain the different substrate specificities for the two active CPD domains,
we decided to perform an extensive molecular docking study. For this purpose, we selected six
peptides, based on the different experimental ratio values observed (i.e. including good, weak
and non-substrates for both domains I and II) shown in Table 3 and S9 Table. The longest
peptides were truncated to 7 C-terminal residues in order to simplify the docking calculations.
The final set of peptides included TITGQKR, LVTDLTK,GAAAGQR, FAATSFR,VDPVNFK
and SALGEPKK. The analysis of the best docking poses for these peptides did not explain the
different substrate specificity of the two domains, in terms of docking score or particular pep-
tide/receptor interactions. For instance, the best docking poses obtained for VDPVNFK and
FAATSFR peptides show very similar interactions, which does not explain why these two
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peptides have different preference towards the CPD domain I. Therefore, we performed an
additional analysis of the docking results, based on the number of expectedly correct docking
solutions found within all resulting docking poses for each peptide. The criteria to consider a
docking peptide pose as correct are based on the following features: the center of mass of the
P1’ and P1 residues should be within 10 Å distance from the center of mass of CPD domain I
Asp268 (S1’ pocket) and Glu315 (S1 pocket) residues, respectively, or from CPD domain II
Asp682 (S1’ pocket) and Glu727 (S1 pocket) residues, respectively. These criteria are likely to
describe the expected general interactions in peptide binding as discussed in the previous sec-
tion. From this analysis of the docking results, we found that the percentage of correct docking
solutions (respect to 101 docking poses analyzed) for each peptide is a good indicator of the
observed cleavage of that peptide by each domain; i.e., the higher the percentage of correct
poses, the better performance as substrate in the experimental data (S9 Table and S5 Fig). For
instance, a high percentage of correct docking poses for domain I was found in the case of
TITGQKR and FAATSFR peptides. On the other hand, domain II showed preference to bind
correctly TITGQKR, LVTDLTK,FAATSFR and VDPVNFK.
Discussion
The primary goal of the present study was the detailed comparison of the substrate specificity
of the first and second catalytic domains of CPD, as well as testing the third carboxypeptidase-
like domain for catalytic activity using a broad array of peptides. CPD is the only member of
the MCP family that contains multiple carboxypeptidase domains [11,15,16]. Proteolytic
enzymes with multiple catalytic sites are rare in nature, especially enzymes with catalytic sites
that perform generally similar roles such as domains I and II of CPD. Angiotensin-converting
enzyme (ACE) is another peptidase with two active domains in most species and tissues (the
form produced in sperm contains a single catalytic domain). The two domains of ACE have
similar catalytic activities that differ mainly in their sensitivity to chloride and substrate prefer-
ences [56,57]. Another group of enzymes with multiple domains that perform related catalytic
functions are the polyserases. As with CPD, the polyserases contain enzymatically active and
inactive domains of unknown function. Polyserase-1 is post-translationally cleaved into dis-
tinct subunits that contain a single catalytic activity, but polyserase-2 and -3 remain intact as
multi-domain-containing proteins [58–60]. The presence of multiple catalytically active
domains can increase the diversity of substrates cleaved, or the efficiency of the enzyme under
different cellular conditions. Both appear to be the case for the two active domains of CPD.
One important contribution of the present study is that human CPD domain I and II have
distinct pH optima, with domain I working best at neutral pH while domain II is optimal at
mildly acidic pH values. This observation is consistent with the properties previously reported
for duck and Drosophila CPD [16,22]. indicating that this feature is highly conserved through
hundreds of millions of years of evolution. Although CPD is primarily detected in the trans
Golgi network, its presence there is not static. CPD is present in vesicles that bud from the
trans Golgi, but is retrieved from these vesicles and sorted back to the trans Golgi. CPD is also
transiently found on the cell surface, where it is internalized and a fraction is transported
through the endocytic pathway back to the trans Golgi network [17]. The pH of each of these
compartments is different, ranging from neutral (the cell surface) to slightly acidic (the trans
Golgi network) to acidic (endosomes). The broad pH range of CPD domain II implies that this
activity is functional in the various cellular compartments, while CPD domain I is optimally
active on the cell surface where the pH is neutral.
Another important finding of the present study is that human CPD domain I and II have
differences in their substrate specificities. Both are specific for C-terminal basic residues, with
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no detectable cleavage of peptides with non-basic residues on the C-terminus. The present
study tested dozens of peptides in a peptidomic assay, and extended the previous studies per-
formed with duck and Drosophila CPD which tested a small number of substrates [16,22]. The
preference of CPD domain I for Arg over Lys, and the broad ability of domain II to cleave
both Arg and Lys with comparable efficiency was previously noted in studies that tested duck
and Drosophila CPD with a single pair of peptides that differed only in the C-terminal residue
[16,22]. The present study tested more than 100 peptides, and while each domain was able to
cleave either Lys or Arg from some peptides, there was a clear preference for domain I to cleave
Arg and not Lys. Interestingly, despite this strict specificity towards basic residues of both
domains, in our study we found some peptides containing this residue that were not cleaved
by domain I or II of CPD. These peptides contained Pro, Asp or Ile in P1 position, confirming
that other residues different from the P1’ affect the efficiency of this human enzyme. Taken
together with the pH optima, it appears that when present on the cell surface, CPD domain I
will be active and cleave peptides/proteins with C-terminal Arg, while CPD present in the
trans Golgi and endocytic pathways will have domain II active and cleave both C-terminal Lys
and Arg.
Previous studies using small numbers of substrates have found that other members of the
M14B subfamily of MCPs are more efficient at cleaving C-terminal Arg than Lys. For example,
CPM cleaves Met5-Arg6-enkephalin with a kcat of 934 min-1 and Km of 46 μM, whereas Met5-
Lys6-enkephalin is cleaved with kcat of 663 min-1 and Km of 375 μM [61]. Other studies evalu-
ated the specificity of MCPs using peptides with C-terminal Arg or Lys residues as competitive
inhibitors. For example, CPE is inhibited by Leu5-Lys6-enkephalin with a ki of 174 μM and
by Leu5-Arg6-enkephalin with a ki of 83 μM [62]. CPZ is inhibited by hippuryl-Arg but not
by hippuryl-Lys [63]. Taken together with the present studies, CPZ and CPM are like CPD
domain I with a strong preference for C-terminal Arg over Lys, while CPE and CPN are more
like CPD domain II which does not have a marked preference for one basic residue over
another. One residue within the substrate binding pocket that correlates with selectivity is the
residue in position equivalent to Leu203 in CPA1. In CPD domain I Ser264 is present in this
position, while in CPD domain II an Asn678 is present (Fig 10). Similarly, CPM and CPZ con-
tain a Ser in this position, and CPE and CPN contain Asn. Perhaps the smaller side chain of
the Ser (versus Asn) within the binding site has a superior capability to fit and facilitate the
establishment of contacts between the guanidine group of the C-terminal scissile Arg residue,
leading to major preference for Arg- versus Lys-containing substrates. The analysis of the
docking landscape suggests that there might be some kinetic effects involved in the processes
of approaching and entering of the peptides into the active site, which are not fully explained
by the structure and energetics of the best docking pose alone. These docking results are con-
sistent with the experimental finding that peptides with a C-terminal lysine have less prefer-
ence for the active site of domain I, whereas peptides with a C-terminal arginine bind both
domains, with a slight preference for domain I.
Another finding of the present study is that the third carboxypeptidase-like domain of
human CPD is inactive as a carboxypeptidase when tested with a fluorescent substrate at a wide
range of pH values, or with a wide array of peptides at pH 6.5. In no case was carboxypeptidase
activity detected for the form of CPD with mutations in a key catalytic residue in domain I and
II. This observation fits with previous studies on duck and Drosophila CPD, which tested a
small number of substrates [16,22]. This observation is also consistent with the lack of con-
served active site, substrate-binding, and metal-binding residues in the third domain of CPD.
For example, the critical active site Glu (Glu270 using bovine CPA1 numbering) is a Tyr in the
third domain of human and duck CPD. Most of the changes in active site residues found in the
third domain of CPD are conserved between human and duck, suggesting that these differences
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are not simply random events but are important for the function of this domain. One possibility
is that the third domain functions in peptide binding. While Glu270 is essential for catalytic
activity, it is not required for substrate binding, and substitution of Gln for Glu permits the pro-
tein to bind peptides but not hydrolyze them. Results from our peptide docking experiments
with the tetrapeptide GQKR support this hypothesis.
Three other members of the M14B subfamily of MCPs are also inactive towards standard
carboxypeptidase substrates. Two of these, CPX2 [64] and AEBP1/ACLP [65] also contain Tyr
in place of the critical active site Glu270, suggesting that this Tyr is important. The third inac-
tive member of this subfamily, CPX1, does contain Glu in the comparable position but is miss-
ing other critical active site and substrate-binding residues. Other families of enzymes contain
members that are considered catalytically inactive, and the functions of most of these proteins
are not yet known [58–60,66]. Recently, AEBP1/ACLP was found to induce phosphorylation
and nuclear translocation of Smad3, and this was dependent on TGFβ receptor binding and
kinase activity [67]. Some of the active carboxypeptidases appear to have functions that are
independent of their catalytic activity. For example, CPE was proposed to function as an extra-
cellular trophic factor that protected neurons from hydrogen peroxide-, staurosporine- and
glutamate-induced cell death, and this effect did not require CPE enzyme activity (although it
did require amounts of CPE much higher than would be expected to be physiological) [68].
CPM was reported to be a positive allosteric modulator of the kinin B1 receptor, and this
action is independent of CPM enzyme activity [69]. The emerging concept is that some car-
boxypeptidases have multiple functions, including both catalytic and non-catalytic roles, while
the inactive members of this gene family like CPD domain III would only have non-catalytic
roles.
Taken together, our results establish that both catalytically active domains of CPD play
important physiological roles by cleaving a broad range of peptide and protein substrates with
C-terminal basic residues or Arg and Lys in the trans-Golgi network, within the secretory and
endocytic pathways and in the cell membrane. Although both active domains display a partial
overlap of their substrate preferences, our results demonstrate that each active CPD domain
has evolved to divergent substrate specificities conserved through evolution. Moreover, the
third domain is catalytically inactive against a wide spectrum of peptides, and the biological
function of this domain remains unknown.
Supporting information
S1 Fig. Relative amount of product formed by three different dansylated tripeptides incu-
bated with various amount of purified rhCPD. Reactions containing 200 μM dansyl-Phe-
Ala-Arg (filled circles), dansyl-Phe-Gly-Arg (filled squares) or dansyl-Phe-Pro-Arg (triangles/
solid line) were incubated with different amounts of enzyme in a 100 mM Tris-acetate, pH 6.5,
150 mM NaCl buffer for 60 min at 37˚C.
(TIF)
S2 Fig. Pharmacophore models of the active sites of human CPD domains I, II and III.
Acceptor and donor maps for domain I (A and D), II (B and E) and III (C and F). Hydrogen
bond acceptors and donors are indicated with a red or blue contour mesh, respectively.
(TIF)
S3 Fig. Alignment of human CPD (Uniprot O75976) domains I, II and III, and human
CPM (Uniprot P14384). Metal binding residues, catalytic residues, and important substrate
binding residues are shown in bold and boxed. Stars above the sequence indicate residues
involved in zinc binding. Residues in bold and non-boxed correspond to those residues within
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cate equivalent positions according to the standard numbering system for bovine CPA.
(TIF)
S4 Fig. Detailed view of the pose of the arginine from GQKR peptide at the S1’ regions of
CPD domains I (A) and II (B), which mainly differ in the residue that corresponds to Leu203
of bovine CPA1 and Ser198 of CPM, Ser264 in domain I and Ans678 in domain II.
(TIF)
S5 Fig. Scatter plot showing the correlation between the experimental enzyme/control
ratio observed in peptidomics experiments and the number of good poses found in the
docking studies.
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